Success Metrics

Active Trials
5(100%)

Phase Distribution

Ph phase_2
2
40%
Ph phase_1
3
60%

Phase Distribution

3

Early Stage

2

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
2(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

5

all time

Status Distribution
Active(5)

Detailed Status

Recruiting5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
5
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 13 (60.0%)
Phase 22 (40.0%)

Trials by Status

recruiting5100%

Recent Activity

5 active trials
Showing 5 of 5
recruitingphase_2

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

NCT07082686
recruitingphase_1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

NCT06656494
recruitingphase_2

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

NCT06378138
recruitingphase_1

The Study of ICP-248 in Patients With Mature B-cell Malignancies

NCT05728658
recruitingphase_1

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

NCT06351527

Clinical Trials (5)

Showing 5 of 5 trials
NCT07082686Phase 2

A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)

Recruiting
NCT06656494Phase 1

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

Recruiting
NCT06378138Phase 2

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Recruiting
NCT05728658Phase 1

The Study of ICP-248 in Patients With Mature B-cell Malignancies

Recruiting
NCT06351527Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Recruiting

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5